Current Treatment Options for Malignant Melanoma
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 55 (6) , 791-799
- https://doi.org/10.2165/00003495-199855060-00006
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Fotemustine in the Treatment of Brain Primary Tumors and MetastasesCancer Investigation, 1994
- Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazineEuropean Journal Of Cancer, 1993
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Fotemustine plus dacarbazine in advanced stage III malignant melanomaEuropean Journal Of Cancer, 1992
- Fotemustine plus dacarbazine for malignant melanomaEuropean Journal Of Cancer, 1992
- Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma—an effective combination with unexpected toxicityEuropean Journal Of Cancer, 1992
- High-Dose Cisplatin and Dacarbazine in the treatment of Metastatic MelanomaJNCI Journal of the National Cancer Institute, 1990
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Gangliosides of normal and neoplastic human melanocytesBiochemical and Biophysical Research Communications, 1984
- A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous MelanomaNew England Journal of Medicine, 1982